UNITED CAPITAL FINANCIAL ADVISORS, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
UNITED CAPITAL FINANCIAL ADVISORS, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$287,111
+4.2%
7,516
-1.6%
0.00%0.0%
Q2 2023$275,539
-7.8%
7,639
-2.4%
0.00%0.0%
Q1 2023$298,875
-42.0%
7,826
-13.6%
0.00%
-33.3%
Q4 2022$515,514
+44.8%
9,060
+0.7%
0.00%
+50.0%
Q3 2022$356,000
-53.7%
8,995
-48.5%
0.00%
-50.0%
Q2 2022$769,000
+113.6%
17,468
+93.8%
0.00%
+100.0%
Q1 2022$360,0000.0%9,015
+0.6%
0.00%0.0%
Q4 2021$360,000
-1.1%
8,965
+0.1%
0.00%0.0%
Q3 2021$364,000
-10.6%
8,960
-0.1%
0.00%0.0%
Q2 2021$407,000
+8.8%
8,9650.0%0.00%0.0%
Q1 2021$374,000
-2.3%
8,9650.0%0.00%0.0%
Q4 2020$383,000
+63.0%
8,965
+0.1%
0.00%0.0%
Q3 2020$235,000
-2.1%
8,9600.0%0.00%0.0%
Q2 2020$240,000
+96.7%
8,960
-30.2%
0.00%
+100.0%
Q1 2016$122,000
-45.3%
12,8430.0%0.00%
-66.7%
Q4 2015$223,000
+29.7%
12,8430.0%0.00%
+50.0%
Q3 2015$172,000
-40.7%
12,8430.0%0.00%
-33.3%
Q2 2015$290,000
+50.3%
12,843
-1.1%
0.00%
+50.0%
Q1 2015$193,000
-8.1%
12,985
-40.1%
0.00%0.0%
Q4 2014$210,000
+130.8%
21,674
+116.7%
0.00%0.0%
Q3 2014$91,000
-31.6%
10,000
-4.8%
0.00%
-33.3%
Q1 2014$133,000
-36.7%
10,500
-25.0%
0.00%
-57.1%
Q4 2013$210,000
+35.5%
14,0020.0%0.01%
+40.0%
Q3 2013$155,00014,0020.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders